You missed the vital bit @madamswer. The announcement you quote specified that the inventory buildup was specifically for paediatric SR aGvHD. (also some use in other areas). No mention of Covid-ARDS. Of course.
Rem-L for Covid-ARDS was not even on the radar at that time. Not outside MSB, anyway.
I share the general excitement here that the $100M will mostly be applied to inventory of Rem-L for ARDS. Possibly for label extensions also. All the signs point to high confidence of management for a very near, very large market for Rem-L.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.030(1.80%) |
Mkt cap ! $2.172B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.74 | $1.67 | $6.647M | 3.897M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 44280 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 26847 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |